Intravenous lacosamide (LCM) in status epilepticus (SE): Weight-adjusted dose and efficacy

被引:17
|
作者
Santamarina, Estevo [1 ]
Gonzalez-Cuevas, Montserrat [1 ]
Toledo, Manuel [1 ]
Jimenez, Marta [2 ]
Luis Becerra, Juan [2 ]
Quilez, Alex [3 ]
Suller, Ana [4 ]
Mauri, J. A. [4 ]
Fernandez, Angel [5 ]
Marinas, Ainhoa [6 ]
Quintana, Manuel [1 ]
Salas Puig, Xavier [1 ]
机构
[1] Hosp Valle De Hebron, Epilepsy Unit, Barcelona, Spain
[2] Hosp Germans Trios & Pujol, Epilepsy Unit, Barcelona, Spain
[3] Hosp Arnau Vilanova, Dept Neurol, Lleida, Spain
[4] Hosp Clin Univ Lozano Blesa, Dept Neurol, Zaragoza, Spain
[5] Hosp Bierzo Ponferrada, Dept Neurol, Leon, Spain
[6] Hosp Univ Cruces, Epilepsy Unit, Baracaldo, Spain
关键词
Lacosamide; Loading dose; Status epilepticus; CONCOMITANT ANTIEPILEPTIC DRUGS; PARTIAL-ONSET SEIZURES; SAFETY; EPILEPSY; EXPERIENCE; PROGNOSIS; CHILDREN; AGE; IV;
D O I
10.1016/j.yebeh.2018.04.025
中图分类号
B84 [心理学]; C [社会科学总论]; Q98 [人类学];
学科分类号
03 ; 0303 ; 030303 ; 04 ; 0402 ;
摘要
Background: Some studies suggest higher efficacy of lacosamide (LCM) in status epilepticus (SE) with higher loading doses; however, this weight-adjusted dose has not been evaluated. Objective: The objective was to evaluate the relationship between loading weight-adjusted dose and efficacy of LCM in SE. Methods: A group of patients with SE treated with LCM from Spanish hospitals was examined retrospectively. Demographic data, type of SE, etiology, response rate, last antiepileptic drug (AED) used, treatment line in which LCM was used, total loading dose, and weight-adjusted dose were collected. Results: One hundred sixty-five cases of SE were collected; 87 (52.7%) patients had nonconvulsive SE. Mean age was 64.2 +/- 17.2 and 60.6% (n = 100) were men. Regarding etiology, SE was considered as acute symptomatic in 85 (51.5%), remote symptomatic in 51 (30.9%), progressive symptomatic in 10 (6.1%), and cryptogenic in 19 (11.5%). Lacosamide was used as the third drug in 46.1%, and as a second option in 28%. In 115 patients, clonazepam had been used as the first option, and no benzodiazepines had been administered in the remaining 50. The median loading dose was 400 mg (100-600 mg), and the weight-adjusted dose was 5 mg/kg (3-6 mg/kg). The response rate was 63.3%, and 55.1% responded within the first 12 h. Efficacy was significantly higher in patients who had taken benzodiazepines at LCM loading doses >5.3 mg/kg (p = 0.006). This relationship was maintained independent of using other concomitant AEDs. However, if benzodiazepines were not taken, this relationship was not found. Conclusions: In adults with benzodiazepine-resistant SE, the response rate to LCM was higher, with weight-adjusted doses above 5.3 mg/kg. (C) 2018 Elsevier Inc. All rights reserved.
引用
收藏
页码:93 / 98
页数:6
相关论文
共 50 条
  • [21] Pharmacokinetics of a fixed dose and a weight-adjusted dose of IV repinotan
    Heinig, R
    Böttcher, M
    STROKE, 2004, 35 (06) : E287 - E287
  • [22] USE OF INTRAVENOUS LACOSAMIDE IN STATUS EPILEPTICUS AND CLUSTER SEIZURES
    Handouk, Y.
    Bomprezzi, C.
    Minardi, C.
    Malagu, S.
    Morresi, S.
    Mauro, A.
    EPILEPSIA, 2012, 53 : 100 - 100
  • [23] EFFICACY OF INTRAVENOUS LACOSAMIDE IN PATIENTS WITH CONVULSIVE VERSUS NON-CONVULSIVE STATUS EPILEPTICUS
    Moreno, E. Y.
    Peleterio, M.
    Bondy, E.
    Dominguez, J.
    Pardellas, E.
    Fernandez, A.
    EPILEPSIA, 2012, 53 : 48 - 48
  • [24] Intravenous Lacosamide in Pediatric Status Epilepticus: An Open-Label Efficacy and Safety Study
    Poddar, Karan
    Sharma, Rohan
    Ng, Yu-Tze
    PEDIATRIC NEUROLOGY, 2016, 61 : 83 - 86
  • [25] Cost reduction in abdominal CT by weight-adjusted dose
    Arana, Estanislao
    Marti-Bonmati, Luis
    Tobarra, Eva
    Sierra, Consuelo
    EUROPEAN JOURNAL OF RADIOLOGY, 2009, 70 (03) : 507 - 511
  • [26] Intravenous lacosamide in status epilepticus: Correlation between loading dose, serum levels, and clinical response
    Perrenoud, Matthieu
    Andre, Pascal
    Alvarez, Vincent
    Staehli, Christine
    Decosterd, Laurent A.
    Rossetti, Andrea O.
    Novy, Jan
    EPILEPSY RESEARCH, 2017, 135 : 38 - 42
  • [27] Safety and Efficacy of Intravenous Lacosamide for Adjunctive Treatment of Refractory Status Epilepticus: A Comparative Cohort Study
    Raoul Sutter
    Stephan Marsch
    Stephan Rüegg
    CNS Drugs, 2013, 27 : 321 - 329
  • [28] Efficacy of intravenous lacosamide as an add-on treatment in refractory status epilepticus: A multicentric prospective study
    Miro, J.
    Toledo, M.
    Santamarina, E.
    Ricciardi, A. C.
    Villanueva, V.
    Pato, A.
    Ruiz, J.
    Juvany, R.
    Falip, M.
    SEIZURE-EUROPEAN JOURNAL OF EPILEPSY, 2013, 22 (01): : 77 - 79
  • [29] Safety and Efficacy of Intravenous Lacosamide for Adjunctive Treatment of Refractory Status Epilepticus: A Comparative Cohort Study
    Sutter, Raoul
    Marsch, Stephan
    Rueegg, Stephan
    CNS DRUGS, 2013, 27 (04) : 321 - 329
  • [30] REFRACTORY STATUS EPILEPTICUS IN CHILDREN: LACOSAMIDE EFFICACY AND SAFETY
    Grosso, S.
    Zamponi, N.
    Cesaroni, E.
    Cappanera, S.
    Verrotti, A.
    Nanni, S.
    Bartolo, R. D.
    Balestri, P.
    EPILEPSIA, 2012, 53 : 178 - 179